Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
On Tuesday, QuidelOrtho Corporation (NASDAQ:QDEL) priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares.
週二,QuideLortho公司(納斯達克股票代碼:QDEL)對凱雷合夥人六開曼控股公司先前宣佈的826萬股二次發行進行了定價。
The selling stockholder will receive all of the proceeds. The company is not selling any shares.
出售股東將獲得所有收益。該公司沒有出售任何股票。
The last reported sale price of QuidelOrtho's common stock on Nov. 19 was $38.58 per share. Goldman Sachs & Co. LLC is acting as the sole underwriter.
QuideLortho普通股最後一次公佈的銷售價格爲每股38.58美元。高盛公司有限責任公司是唯一的承銷商。
William Blair analysts noted that Carlyle sold some of its shares earlier this summer through smaller transactions. At that time, investors had suggested block trades or secondary transactions for any further sales by Carlyle. Tuesday's announcement aligns with these preferences, which investors may view positively.
威廉·布萊爾分析師指出,凱雷今年夏天早些時候通過小額交易出售了部分股票。當時,投資者建議凱雷進行大宗交易或二次交易。週二的公告符合這些偏好,投資者可能會積極看待這些偏好。
While some might interpret this move as a lack of confidence in QuidelOrtho's ongoing improvements, the analysts do not share that view.
儘管有些人可能將這一舉動解釋爲對QuideLortho的持續改善缺乏信心,但分析師並不認同這一觀點。
Instead, they emphasize considering factors like Carlyle's long ownership period, as the firm originally acquired Ortho Clinical in 2014.
相反,他們強調考慮諸如凱雷長期所有權等因素,因爲該公司最初在2014年收購了Ortho Clinical。
William Blair analysts write, "We take this as a long-term net-positive for the stock as it removes one of the overhangs that came up in investor conversations around the name."
威廉·布萊爾分析師寫道:「我們認爲這是該股的長期淨利好因素,因爲它消除了投資者圍繞該名稱的對話中出現的懸而未決的問題。」
William Blair reiterates a Market Perform rating.
威廉·布萊爾重申市場表現評級。
Price Action: QDEL stock is down 4.2% at $36.96 at last check Wednesday.
價格走勢:週三最後一次檢查時,QDEL股價下跌4.2%,至36.96美元。
- Salesforce Tool Aims To Simplify AI Agent Testing, Deployment
- Salesforce 工具旨在簡化 AI 代理的測試和部署
Photo: Shutterstock
照片:Shutterstock